Your browser doesn't support javascript.
loading
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef, Núria; Castillo, Carmen; Mosteiro, Miguel; Pérez, Xavier; Aguilar, Susana; Ruíz-Pace, Fiorella; Gil, Marta; Cuadra, Carmen; Ruffinelli, José Carlos; Martínez, Mercedes; Losa, Ferran; Soler, Gema; Teulé, Àlex; Castany, Roser; Gallego, Rosa; Ruíz, Andrea; Garralda, Elena; Élez, Elena; Vivancos, Ana; Tabernero, Josep; Salazar, Ramon; Dienstmann, Rodrigo; Santos Vivas, Cristina.
Afiliação
  • Mulet Margalef N; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Castillo C; Badalona Applied Research Group in Oncology, B-ARGO, Spain.
  • Mosteiro M; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Pérez X; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Aguilar S; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Ruíz-Pace F; Molecular Pre-Screening Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Gil M; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Cuadra C; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Ruffinelli JC; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Martínez M; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Losa F; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Soler G; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Teulé À; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Castany R; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Gallego R; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Ruíz A; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Garralda E; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Élez E; Research Unit for Molecular Therapy of Cancer (UITM), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Vivancos A; Department of Medical Oncology, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Tabernero J; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Salazar R; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, CIBERONC, Barcelona, Spain.
  • Dienstmann R; Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
  • Santos Vivas C; Oncobell Program (IDIBELL), Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona CIBERONC, Spain.
Mol Oncol ; 17(9): 1908-1916, 2023 09.
Article em En | MEDLINE | ID: mdl-37097008
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas B-raf Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas B-raf Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article